# Cilag AG – FDA 483, Jul 16, 2019

Source: https://www.keypedia.com/records/483/cilag-ag/24f39902-f5af-47ce-b648-514441b550a8

> FDA 483 for Cilag AG on July 16, 2019. Product: drugs. Access full analysis and detailed observations.

---

## Details

- Record Type: 483
- Company Name: Cilag AG
- Inspection Date: 2019-07-16
- Product Type: drugs
- Office Name: Office of Biological Products Operations - Division I
- Summary: An FDA inspection of Cilag AG, a drug manufacturer in Schaffhausen, Switzerland, revealed four observations related to quality system deficiencies. These included issues with equipment maintenance, failure to follow established microbiological test procedures, and incomplete laboratory records for instrument calibration and endotoxin testing traceability. The findings indicate a need for improved adherence to good manufacturing practices and documentation standards.

## Related Documents

- [483 - 2025-06-16](https://www.keypedia.com/records/483/cilag-ag/537b1473-d6a2-423b-ab58-5fa704f72354) — date: June 16, 2025
- [483 - 2024-09-23](https://www.keypedia.com/records/483/cilag-ag/114092e8-2db7-42e9-a655-7fd49de1a4b6) — date: September 23, 2024

## Related Officers

- [Santos E. Camara](https://www.keypedia.com/people/santos-e-camara/18cea942-f6f9-4dec-9ce9-1c01c39009ce)

Company: https://www.keypedia.com/companies/cilag-ag/acb7f670-89b9-4e40-a784-ed06b0282362

Office: https://www.keypedia.com/offices/office-of-biological-products-operations-division-i/49c53dac-7724-4c8c-8708-4f5779ea69c1